289) In addition, these tumor suppressors have important roles in |
290) RING-finger E3s serve as oncoproteins or tumor suppressors in HCC under specific co |
291) a signaling network involving established tumor suppressors including LKB1, TSC2 and |
292) nscripts, can lead to loss-of-function in tumor suppressors or activation of oncogen |
293) miR-106b induced by TGF-β determines the tumor-promoting effects of TGF-β in breas |
294) er cells acquire the ability to evade the tumor-suppressing effects of TGF-β, yet s |
295) This can explain why SAA1.5 has no tumor-suppressive effects. |
296) ents, of whom a majority had laparoscopic tumor excision and partial myocutaneous gl |
297) cases were successfully treated regarding tumor excision by practicing right hemicol |
298) gnosis of an ectopic lymph node or benign tumor, excision via the oral cavity was pe |
299) lysis showed that intracranial transdural tumor extension was correlated with the hi |
300) preoperative LCN deficit had intracranial tumor extension. |
301) endent on the tumor's size and intradural tumor extension. |
302) The tumor had not changed in size subjectively |
303) athological examination revealed that the tumor had progressed to an MGCT after recu |
304) rhabdoid tumor/primitive neuroectodermal tumor had worse outcome. |
305) ere independent prognostic factors of the tumor local control (p = 0.022, 0.019, and |
306) e, and D90 were prognostic factors of the tumor local control and survival (p = 0.13 |
307) nce interval time are factors influencing tumor local control, and the recurrence in |
308) Tumor lysis syndrome, a complication of an |
309) We report tumor lysis syndrome in a patient treated |
310) irst course of trastuzumab, she developed tumor lysis syndrome. |
311) 2f1 or E2f3 led to a significant delay in tumor onset in both oncogenic models, wher |
312) n medulloblastoma incidence and a delayed tumor onset. |
313) Loss of any E2F delayed Neu-induced tumor onset. |
314) used as a carrier of anti-tumor drugs for tumor targeting by intravenous administrat |
315) omising approach to coordinating with the tumor targeting efficacy of ligand-modifie |
316) ene glycol) (PEG) grafting density on the tumor targeting efficacy of nanoparticles |
317) 131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was cal |
318) This process allows the tumor to receive its extensive nutrition d |
319) esis that hypoxia promotes cells in solid tumor to reprogram metabolic pathways in o |
320) In different tumor types due to the intrinsic immunogen |
321) The tumor types in decreasing frequency were a |
|